Vera Therapeutics, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Revenues			16.6	16.6	16.6	16.6	52.5	52.5
Revenue growth			-68.3%	-68.3%	-68.3%	-68.3%
Cost of goods sold			0.0	0.0	0.0	0.0	0.0	0.0
Gross profit			16.6	16.6	16.6	16.6	52.5	52.5
Gross margin			100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Selling, general and administrative [+]			18.8	16.9	14.6	11.9	9.2	6.2
General and administrative			18.8	16.9	14.6	11.9	9.2	6.2
Research and development			55.1	39.0	32.1	22.5	49.6	48.0
Other operating expenses						14.1		49.8
EBITDA [+]			-74.2	-56.0	-44.0	-31.7	-56.6	-51.4
EBITDA growth			31.2%	9.1%	-14.3%	-35.4%
EBITDA margin			-446.0%	-336.7%	-264.2%	-190.2%	-107.8%	-97.8%
Depreciation and amortization			-0.2	0.0	0.2	0.2	-0.5	0.1
EBIT [+]			-74.0	-56.0	-44.1	-31.8	-56.1	-51.5
EBIT growth			31.9%	8.9%	-14.3%	-35.4%
EBIT margin			-444.7%	-336.6%	-265.1%	-191.2%	-106.9%	-98.1%
Non-recurring items [+]						2.6		5.7
Loss (gain) on sale of business								2.7
Interest income, net [+]			0.4	0.0	-0.1	0.0	0.0	-0.1
Interest expense			0.4	0.3	0.1	0.0
Interest income			0.9	0.3	0.0	0.0	0.0	0.0
Other income (expense), net [+]			0.0	-0.5	1.8	1.8	1.7	1.8
Other			1.0	0.6	0.3
Pre-tax income			-73.5	-56.4	-45.0	-32.6	-58.6	-55.5
Income taxes			0.0	0.0	0.0	0.0	0.0	0.0
Tax rate			0.0%	0.0%	0.0%		0.0%	0.0%
Net income			-73.5	-56.4	-45.0	-32.6	-58.6	-55.5
Net margin			-441.4%	-338.8%	-270.2%	-195.9%	-111.7%	-105.7%

Basic EPS [+]			($3.20)	($2.62)	($2.59)	($2.86)	($7.22)	($19.25)
Growth			-55.8%	-86.4%	-98.4%	-98.3%
Diluted EPS [+]			($3.20)	($2.62)	($2.59)	($2.86)	($7.22)	($19.25)
Growth			-55.8%	-86.4%	-98.4%	-98.3%

Shares outstanding (basic) [+]			23.0	21.5	17.4	11.4	8.1	2.9
Growth			183.2%	645.9%	5019.8%	3438.3%
Shares outstanding (diluted) [+]			23.0	21.5	17.4	11.4	8.1	2.9
Growth			183.2%	645.9%	5019.8%	3438.3%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.